One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Contrast Agents/Media Global Market

造影剤/メディア市場ー業界洞察、主要プレーヤー・企業別、成長機会別、最新傾向別、開発別、主要な成長ドライバー別、主要な課題別によってセグメンテーション、予測 2028年


[ 英語タイトル ] Contrast Agents/Media Global Market - Forecast to 2027


Product Code : IQ4IHC00114185
Survey : IQ4I
Publish On : July, 2021
Number of Pages : 460
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4950 / Question Form
5 User USD6750 / Question Form
Enterprise User USD9000 / Question Form
BAYER GROUP
BEIJING BEILU PHARMACEUTICAL CO., LTD.
BRACCO GROUP
DONGKOOK LIFE SCIENCE
FUJIPHARMA CO LTD
GE HEALTHCARE
GUERBET
LANTHEUS MEDICAL IMAGING INC.
SANOCHEMIA PHARMACEUTICAL AG
TAEJOON PHARM CO., LTD.
LIST OF COMPANIES MENTIONED IN THE REPORT
ASCELIA PHARMA AB
BAYER GROUP
BEIJING BEILU PHARMACEUTICALS COMPANY LIMITED
BIEM İLAÇ SAN. AND TIC, INC.
BRACCO GROUP
DAIHAN PHARM. CO. LTD.
DONGKOOK LIFESCIENCE
ESKAY FINE CHEMICALS
FERRIC CONTRAST COMPANY
FUJIFILM HOLDING CORPORATION
FUJIPHARMA CO. LTD
GE COMPANY (GE HEALTHCARE)
GENUS MEDICAL TECHNOLOGIES
GUERBET, LLC
IMAGION BIOSYSTEMS, LTD
IMAX DIAGNOSTIC IMAGING LIMITED
INLIGHTA BIOSCIENCES, LLC
JB CHEMICALS AND PHARMACEUTICALS LTD
JODAS EXPOIM PVT. LTD
LANTHEUS MEDICAL IMAGING
MAGNUS HEALTH
NANOLOGY LABS INC
NANO-THERAPEUTICS
OTSUKA PHARMACEUTICAL CO. LTD. (INTERPHARMA PRAHA)
REGE IMAGING & CINEFILMS PRIVATE LIMITED
REVEAL PHARMACEUTICALS
SANOCHEMIA PHARMAZEUTIKA AG
SPAGO NANOMEDICAL
STELLENCE PHARMSCIENCE PRIVATE LIMITED
TAEJOON PHARM CO. LTD.,
TRIVITRON HEALTHCARE
TRUST BIOSONICS
UNIJULES LIFE SCIENCES LTD
UNIMARK REMEDIES
VB TECHNOCHEMICALS SA
ZHEJIANG STARRY PHARMA

[Report Description]

Chemical substances that improve the visibility of specific organs, tissues, or blood vessels during a diagnostic or interventional imaging investigation are known as contrast agents. These substances are administered directly through veins, arteries, joints, rectally, body cavity or consumed orally. X-ray and computed tomography (CT) imaging exams make use of iodinated and barium-based contrast agents, whereas, Gadolinium-based contrast agents are preferred in MRI (Magnetic Resonance Imaging). These substances improve the reporting or accuracy of how internal structures of the body are working and any associated abnormalities. Ultrasound scans make use of special contrast agents called microbubbles which strongly interact with the ultrasound beam and enhance the details of the heart, liver and kidney.
According to IQ4I analysis, the contrast agents global market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $7,033.5 million by 2027 due to the increasing incidence & prevalence of chronic diseases and demand for diagnostic & interventional radiology procedures, increase in aging population, Expansion of contrast agent indications, the growth of medical imaging in the emerging market, increasing research activities and favorable reimbursement.
The contrast agents/Media global market is segmented by molecule, modality, applications, route of administration, imaging, end-users and geography. Based on the molecule type, the market is segmented into Iodine based [Ionic -Monomer), Non-Ionic (Monomer and Dimer)], Gadolinium-based contrast agents [Macrocyclic (Ionic and Non-Ionic), Linear (Ionic and Non-Ionic)], Microbubble based contrast agent and others which include Barium, and iron. Among the molecules, the iodine-based contrast agents market held the largest market revenue in 2020. The Microbubble segment is expected to grow rapidly at high teen CAGR from 2020 to 2027 due to the increasing number of clinical trials for the expansion of disease indications. Based on ionicity, the Iodine-based contrast agent is segmented into ionic and non-ionic. Non-Ionic Iodine-based contrast agents market accounted for the largest share of 69.5% in 2020 and the market is expected to grow at mid single digit CAGR from 2020 to 2027 due to the advantages of Non-ionic iodine contrast agents over ionic based contrast agents because of lower osmolality, they are better tolerated and they appear to have less toxicity. Non-Ionic Iodine-based contrasts are further segmented by their chemical structure into monomer and dimer. Monomer market accounted for the largest share in 2020 and the market is expected to grow at mid single digit CAGR from 2020 to 2027 as they safer and tolerable when compared to ionic contrast agents and low osmolar agents do not dissociate into a particle in solution and helps in reducing the neurotoxicity. Gadolinium-based contrast agents are segmented into linear and macrocyclic based on the chemical structures. Among them, the Macrocyclic based contrast agents market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the advantages of macrocyclic over linear based contrast agents in terms of stability and less toxicity. Macrocyclic-based contrast agent further segmented into ionic and non-ionic. Among these, Non-Ionic accounted for the largest revenue in 2020. The ionic segment is growing at high single digit CAGR from 2020 to 2027.
The contrast agents market by modality is segmented into X-ray/CT, MRI and Ultrasound. X-Ray/CT market held the largest market revenue in 2020 and is expected grow at mid single digit CAGR from 2020 to 2027. The ultrasound segment is growing rapidly at high teen CAGR from 2020 to 2027 due to increased use in diagnostic procedures especially echocardiography, focal liver lesions and ultrasonography of the urinary tract.
The contrast agents market by applications is segmented into cardiovascular, cancer, gastrointestinal, musculoskeletal, neurology, nephrology, obstetrics & gynecology, urology and others which include the neck, liver and salivary gland imaging. The cardiovascular market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the increasing incidence and prevalence of cardiovascular diseases such as coronary heart disease, heart attack, atherosclerosis & others, increase utilization of contrast agents in coronary angiography procedures and approval contrast agents for cardiovascular indications. Cancer is the fastest-growing segment at high single digit CAGR from 2020 to 2027 due to increasing incidence and prevalence of various types of cancer, expansion of indication of contrast agents for cancer and emerging approach of development of targeted nanoparticle-based contrast agents for cancer. According to IQ4I analysis, the Contrast Agents market by route of administration is segmented into intravascular, oral, rectal and others which include (intrathecal and body cavity). Intravascular accounted for the largest share in 2020 and is the fastest-growing segment with a projected high single digit CAGR from 2020 to 2027.
The contrast Agents market by imaging is segmented into diagnostic and interventional imaging. The diagnostic imaging market held the largest market revenue in 2020 and is expected to grow at high single digit CAGR from 2020 to 2027. Interventional imaging is the fastest-growing segment with low teen CAGR from 2020 to 2027 due to an increase in image guided procedures and an increase in the aging population who usually opt for minimally invasive procedures.
Based on end-user, contrast agents market is segmented into hospitals, diagnostic & ambulatory surgical centers and others which include academic and research institutes. The hospitals market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the rise in demand for the diagnosis and interventional treatment of diseases using CT or X-Ray, MRI and ultrasound imaging procedures. Diagnostic & Ambulatory surgical centers are the fastest-growing segment with a projected high single digit CAGR from 2020 to 2027 due to an increase in the number of diagnostic procedures related to musculoskeletal (arthroscopy, imaging of spine), gastrointestinal (imaging of the abdomen, GI tract) and obstetrics & gynecology (hysterosalpingography).
Based on the region, the contrast agent global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K and Rest of Europe), Asia-Pacific (Japan, China, South Korea, and Rest of APAC) and Rest of the world (Turkey, Brazil, Rest of Latin America and Middle East & Africa). North America accounted for the largest and fastest-growing region with revenue in 2020 by growing at high single digit CAGR from 2020 to 2027. The factors such as increasing incidence and prevalence of the chronic disease, increase in aging population, approval of contrast agents for various indications, expanding indications of contrast agents, increasing number of contrast mediated diagnostic and interventional procedures, approach for the development of novel contrast agents by the startup companies and favorable reimbursement will drive North America contrast agent market.
The contrast agents global market is consolidated. The top five players occupy major share of the market share and the remaining XX% of the market is occupied by other players. All the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring companies for product expansion. Some of the key players of the contrast agents market are GE Company (GE Healthcare) (U.S.), Bayer Group (Germany), Guerbet (France), Taejoon Pharm Co. Ltd., (South Korea), Beijing Beilu Pharmaceuticals Company Limited (China), Bracco Group (Italy), Fujifilm Holding Corporation (Japan), Sanochemia Pharmazeutika AG (Austria), Dongkook Lifescience (Korea), Lantheus medical imaging (U.S.) and Fujipharma Co. Ltd (Japan).
Chemical substances that improve the visibility of specific organs, tissues, or blood vessels during a diagnostic or interventional imaging investigation are known as contrast agents. These substances are administered directly through veins, arteries, joints, rectally, body cavity or consumed orally. X-ray and computed tomography (CT) imaging exams make use of iodinated and barium-based contrast agents, whereas, Gadolinium-based contrast agents are preferred in MRI (Magnetic Resonance Imaging). These substances improve the reporting or accuracy of how internal structures of the body are working and any associated abnormalities. Ultrasound scans make use of special contrast agents called microbubbles which strongly interact with the ultrasound beam and enhance the details of the heart, liver and kidney.
According to IQ4I analysis, the contrast agents global market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $7,033.5 million by 2027 due to the increasing incidence & prevalence of chronic diseases and demand for diagnostic & interventional radiology procedures, increase in aging population, Expansion of contrast agent indications, the growth of medical imaging in the emerging market, increasing research activities and favorable reimbursement.
The contrast agents/Media global market is segmented by molecule, modality, applications, route of administration, imaging, end-users and geography. Based on the molecule type, the market is segmented into Iodine based [Ionic -Monomer), Non-Ionic (Monomer and Dimer)], Gadolinium-based contrast agents [Macrocyclic (Ionic and Non-Ionic), Linear (Ionic and Non-Ionic)], Microbubble based contrast agent and others which include Barium, and iron. Among the molecules, the iodine-based contrast agents market held the largest market revenue in 2020. The Microbubble segment is expected to grow rapidly at high teen CAGR from 2020 to 2027 due to the increasing number of clinical trials for the expansion of disease indications. Based on ionicity, the Iodine-based contrast agent is segmented into ionic and non-ionic. Non-Ionic Iodine-based contrast agents market accounted for the largest share of 69.5% in 2020 and the market is expected to grow at mid single digit CAGR from 2020 to 2027 due to the advantages of Non-ionic iodine contrast agents over ionic based contrast agents because of lower osmolality, they are better tolerated and they appear to have less toxicity. Non-Ionic Iodine-based contrasts are further segmented by their chemical structure into monomer and dimer. Monomer market accounted for the largest share in 2020 and the market is expected to grow at mid single digit CAGR from 2020 to 2027 as they safer and tolerable when compared to ionic contrast agents and low osmolar agents do not dissociate into a particle in solution and helps in reducing the neurotoxicity. Gadolinium-based contrast agents are segmented into linear and macrocyclic based on the chemical structures. Among them, the Macrocyclic based contrast agents market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the advantages of macrocyclic over linear based contrast agents in terms of stability and less toxicity. Macrocyclic-based contrast agent further segmented into ionic and non-ionic. Among these, Non-Ionic accounted for the largest revenue in 2020. The ionic segment is growing at high single digit CAGR from 2020 to 2027.
The contrast agents market by modality is segmented into X-ray/CT, MRI and Ultrasound. X-Ray/CT market held the largest market revenue in 2020 and is expected grow at mid single digit CAGR from 2020 to 2027. The ultrasound segment is growing rapidly at high teen CAGR from 2020 to 2027 due to increased use in diagnostic procedures especially echocardiography, focal liver lesions and ultrasonography of the urinary tract.
The contrast agents market by applications is segmented into cardiovascular, cancer, gastrointestinal, musculoskeletal, neurology, nephrology, obstetrics & gynecology, urology and others which include the neck, liver and salivary gland imaging. The cardiovascular market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the increasing incidence and prevalence of cardiovascular diseases such as coronary heart disease, heart attack, atherosclerosis & others, increase utilization of contrast agents in coronary angiography procedures and approval contrast agents for cardiovascular indications. Cancer is the fastest-growing segment at high single digit CAGR from 2020 to 2027 due to increasing incidence and prevalence of various types of cancer, expansion of indication of contrast agents for cancer and emerging approach of development of targeted nanoparticle-based contrast agents for cancer. According to IQ4I analysis, the Contrast Agents market by route of administration is segmented into intravascular, oral, rectal and others which include (intrathecal and body cavity). Intravascular accounted for the largest share in 2020 and is the fastest-growing segment with a projected high single digit CAGR from 2020 to 2027.
The contrast Agents market by imaging is segmented into diagnostic and interventional imaging. The diagnostic imaging market held the largest market revenue in 2020 and is expected to grow at high single digit CAGR from 2020 to 2027. Interventional imaging is the fastest-growing segment with low teen CAGR from 2020 to 2027 due to an increase in image guided procedures and an increase in the aging population who usually opt for minimally invasive procedures.
Based on end-user, contrast agents market is segmented into hospitals, diagnostic & ambulatory surgical centers and others which include academic and research institutes. The hospitals market accounted for the largest share in 2020 and the market is expected to grow at high single digit CAGR from 2020 to 2027 due to the rise in demand for the diagnosis and interventional treatment of diseases using CT or X-Ray, MRI and ultrasound imaging procedures. Diagnostic & Ambulatory surgical centers are the fastest-growing segment with a projected high single digit CAGR from 2020 to 2027 due to an increase in the number of diagnostic procedures related to musculoskeletal (arthroscopy, imaging of spine), gastrointestinal (imaging of the abdomen, GI tract) and obstetrics & gynecology (hysterosalpingography).
Based on the region, the contrast agent global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K and Rest of Europe), Asia-Pacific (Japan, China, South Korea, and Rest of APAC) and Rest of the world (Turkey, Brazil, Rest of Latin America and Middle East & Africa). North America accounted for the largest and fastest-growing region with revenue in 2020 by growing at high single digit CAGR from 2020 to 2027. The factors such as increasing incidence and prevalence of the chronic disease, increase in aging population, approval of contrast agents for various indications, expanding indications of contrast agents, increasing number of contrast mediated diagnostic and interventional procedures, approach for the development of novel contrast agents by the startup companies and favorable reimbursement will drive North America contrast agent market.
The contrast agents global market is consolidated. The top five players occupy major share of the market share and the remaining XX% of the market is occupied by other players. All the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring companies for product expansion. Some of the key players of the contrast agents market are GE Company (GE Healthcare) (U.S.), Bayer Group (Germany), Guerbet (France), Taejoon Pharm Co. Ltd., (South Korea), Beijing Beilu Pharmaceuticals Company Limited (China), Bracco Group (Italy), Fujifilm Holding Corporation (Japan), Sanochemia Pharmazeutika AG (Austria), Dongkook Lifescience (Korea), Lantheus medical imaging (U.S.) and Fujipharma Co. Ltd (Japan).


1 EXECUTIVE SUMMARY 26
2 INTRODUCTION 34
2.1 KEY TAKEAWAYS 34
2.2 REPORT SCOPE 35
2.3 REPORT DESCRIPTION 35
2.4 MARKETS COVERED 38
2.5 STAKEHOLDERS 41
2.6 RESEARCH METHODOLOGY 41
2.6.1 MARKET SIZE ESTIMATION 44
2.6.2 MARKET CRACKDOWN AND DATA TRIANGULATION 46
2.6.3 SECONDARY SOURCES 47
2.6.4 PRIMARY SOURCES 48
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 48
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 49
2.6.7 ASSUMPTIONS 49
2.6.7.1 Procedural volume assumptions 51
3 MARKET ANALYSIS 52
3.1 INTRODUCTION 52
3.2 MARKET SEGMENTATION 53
3.3 FACTORS INFLUENCING MARKET 55
3.3.1 DRIVERS AND OPPORTUNITIES 56
3.3.1.1 Increasing demand for diagnostic and interventional radiology procedures 56
3.3.1.2 Increase in aging population 58
3.3.1.3 Expansion in indications of contrast media 59
3.3.1.4 Increasing research activities towards the development of novel contrast agents 60
3.3.1.5 The growth of medical imaging technologies in emerging markets 62
3.3.1.6 Favorable reimbursement 63
3.3.2 RESTRAINTS AND THREATS 64
3.3.2.1 Side effect associated with contrast agents 64
3.3.2.2 Shortage of radiologists 66
3.3.2.3 Availability of alternative products 66
3.3.2.4 Stringent regulations for contrast agents 68
3.4 REGULATORY GUIDELINES 69
3.4.1 UNITED STATES 69
3.4.2 EUROPE 71
3.4.3 CHINA 72
3.4.4 JAPAN 73
3.4.5 SOUTH KOREA 74
3.4.6 INDIA 74
3.5 REIMBURSEMENT SCENARIO 75
3.5.1 REIMBURSEMENT TABLE 77
3.6 TECHNOLOGICAL ADVANCEMENTS 79
3.6.1 INTRODUCTION 79
3.6.2 ADVANCEMENTS IN COMPUTED TOMOGRAPHY TECHNOLOGY 79
3.6.3 NANOPARTICLES BASED CONTRAST AGENTS 80
3.6.4 MULTIMODAL CONTRAST AGENTS 83
3.6.5 MANGANESE-BASED MRI CONTRAST AGENTS 84
3.6.6 APPLICATION OF AI IN CONTRAST IMAGING 85
3.6.7 BISMUTH BASED CONTRAST AGENTS 85
3.6.8 SUPRAMOLECULAR MACROMOLECULAR ORGANIC RADICAL
CONTRAST AGENT 86
3.6.9 XENON MAGNETIC RESONANCE IMAGING 87
3.6.10 UPCOMING TECHNOLOGIES/PRODUCTS 88
3.7 IMPACT OF COVID-19 ON IMAGING PROCEDURES 91
3.8 CLINICAL TRIALS 94
3.9 SUPPLY CHAIN ANALYSIS 96
3.10 PORTER’S FIVE FORCE ANALYSIS 99
3.10.1 THREAT OF NEW ENTRANTS 100
3.10.2 THREAT OF SUBSTITUTES 102
3.10.3 BARGAINING POWER OF SUPPLIERS 103
3.10.4 BARGAINING POWER OF BUYERS 103
3.10.5 RIVALRY AMONG EXISTING COMPETITORS 104
3.11 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 105
3.11.1 GLOBAL CONTRAST AGENT GLOBAL MARKET 105
3.11.2 GLOBAL X-RAY/CT CONTRAST AGENTS MARKET 109
3.11.3 GLOBAL MRI CONTRAST AGENTS MARKET 112
3.11.4 GLOBAL ULTRASOUND BASED CONTRAST AGENTS MARKET 115
3.12 COMPUTED TOMOGRAPHY MARKET – NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE 117
3.12.1 GLOBAL COMPUTED TOMOGRAPHY MARKET-NUMBER OF SCANS,
VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE 117
3.12.2 NORTH AMERICA COMPUTED TOMOGRAPHY MARKET-NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE 121
3.12.3 EUROPE COMPUTED TOMOGRAPHY MARKET-NUMBER OF SCANS,
VOLUME OF CONTRAST AGENT CONSUMED,AND MARKET SIZE 122
3.12.4 APAC COMPUTED TOMOGRAPHY MARKET-NUMBER OF SCANS,
VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE 124
3.12.5 ROW COMPUTED TOMOGRAPHY MARKET-NUMBER OF SCANS,
VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE 125
3.13 MAGNETIC RESONANCE IMAGING MARKET-PROCEDURE VOLUME,
VOLUME OF CONTRAST AGENT CONSUMED & MARKET SIZE 126
3.13.1 GLOBAL MAGNETIC RESONANCE IMAGING MARKET-NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE 126
3.13.2 NORTH AMERICA MAGNETIC RESONANCE IMAGING MARKET-NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE 131
3.13.3 EUROPE MAGNETIC RESONANCE IMAGING MARKET-NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE 133
3.13.4 APAC MAGNETIC RESONANCE IMAGING MARKET-NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE 134
3.13.5 ROW MAGNETIC RESONANCE IMAGING MARKET-NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE 136
4 CONTRAST AGENTS GLOBAL MARKET, BY MOLECULE 140
4.1 INTRODUCTION 140
4.2 IODINE BASED CONTRAST MEDIA 143
4.2.1 IODINE BASED IONIC CONTRAST MEDIA 149
4.2.2 IODINE BASED NON-IONIC CONTRAST MEDIA 151
4.2.2.1 Monomer 154
4.2.2.2 Dimer 156
4.3 GADOLINIUM-BASED CONTRAST MEDIA 157
4.3.1 MACROCYCLIC 161
4.3.1.1 Ionic 164
4.3.1.2 Non-Ionic 166
4.3.2 LINEAR 167
4.3.2.1 Ionic 169
4.3.2.2 Non-Ionic 170
4.4 MICROBUBBLE BASED CONTRAST MEDIA 171
4.5 OTHER CONTRAST MEDIA 174
5 CONTRAST AGENTS GLOBAL MARKET, BY MODALITY 178
5.1 INTRODUCTION 178
5.2 X-RAY/COMPUTED TOMOGRAPHY (CT) 181
5.3 MAGNETIC RESONANCE IMAGING (MRI) 184
5.4 ULTRASOUND 187
6 CONTRAST AGENTS GLOBAL MARKET, BY APPLICATION 189
6.1 INTRODUCTION 189
6.2 CARDIOVASCULAR 191
6.3 CANCER 195
6.4 GASTROINTESTINAL 199
6.5 MUSCULOSKELETAL 202
6.6 NEUROLOGY 205
6.7 NEPHROLOGY 208
6.8 OBSTETRICS AND GYNECOLOGY 211
6.9 UROLOGY 213
6.10 OTHERS 215
7 CONTRAST AGENTS GLOBAL MARKET, BY ROUTE OF ADMINISTRATION 218
7.1 INTRODUCTION 218
7.2 INTRAVASCULAR 221
7.3 ORAL 223
7.4 RECTAL 226
7.5 OTHERS 228
8 CONTRAST AGENTS GLOBAL MARKET, BY IMAGING 231
8.1 INTRODUCTION 231
8.2 DIAGNOSTIC IMAGING 234
8.3 INTERVENTIONAL IMAGING 236
9 CONTRAST AGENTS GLOBAL MARKET, BY END-USERS 239
9.1 INTRODUCTION 239
9.2 HOSPITAL 241
9.3 DIAGNOSTIC & AMBULATORY SURGICAL CENTERS 244
9.4 OTHER END-USER 246
10 REGIONAL ANALYSIS 249
10.1 INTRODUCTION 249
10.2 NORTH AMERICA 253
10.2.1 THE U.S. 274
10.2.2 REST OF NORTH AMERICA 282
10.3 EUROPE 288
10.3.1 GERMANY 307
10.3.2 FRANCE 313
10.3.3 THE U.K. 319
10.3.4 REST OF EUROPE 324
10.4 ASIA-PACIFIC 329
10.4.1 JAPAN 348
10.4.2 CHINA 354
10.4.3 SOUTH KOREA 360
10.4.4 REST OF APAC 365
10.5 REST OF THE WORLD 371
10.5.1 TURKEY 390
10.5.2 BRAZIL 395
10.5.3 LATAM AND MIDDLE EAST & AFRICA 400
11 COMPETITIVE LANDSCAPE 405
11.1 INTRODUCTION 405
11.2 APPROVALS 406
11.3 AGREEMENT 411
11.4 ACQUISITION 411
12 MAJOR PLAYER PROFILES 413
12.1 BAYER GROUP 413
12.1.1 OVERVIEW 413
12.1.2 FINANCIALS 414
12.1.3 PRODUCT PORTFOLIO 416
12.1.4 KEY DEVELOPMENTS 417
12.1.5 BUSINESS STRATEGY 417
12.1.6 SWOT ANALYSIS 418
12.2 BEIJING BEILU PHARMACEUTICAL CO., LTD 419
12.2.1 OVERVIEW 419
12.2.2 FINANCIALS 419
12.2.3 PRODUCT PORTFOLIO 420
12.2.4 KEY DEVELOPMENTS 420
12.2.5 BUSINESS STRATEGY 420
12.2.6 SWOT ANALYSIS 421
12.3 BRACCO GROUP 422
12.3.1 OVERVIEW 422
12.3.2 FINANCIALS 422
12.3.3 PRODUCT PORTFOLIO 423
12.3.4 KEY DEVELOPMENTS 424
12.3.5 BUSINESS STRATEGY 424
12.3.6 SWOT ANALYSIS 426
12.4 DONGKOOK LIFE SCIENCE 427
12.4.1 OVERVIEW 427
12.4.2 FINANCIALS 427
12.4.3 PRODUCT PORTFOLIO 427
12.4.4 KEY DEVELOPMENTS 428
12.4.5 BUSINESS STRATEGY 428
12.4.6 SWOT ANALYSIS 429
12.5 FUJIPHARMA CO LTD 430
12.5.1 OVERVIEW 430
12.5.2 FINANCIALS 431
12.5.3 PRODUCT PORTFOLIO 433
12.5.4 KEY DEVELOPMENTS 433
12.5.5 BUSINESS STRATEGY 433
12.5.6 SWOT ANALYSIS 434
12.6 GE COMPANY (GE HEALTHCARE) 435
12.6.1 OVERVIEW 435
12.6.2 FINANCIALS 436
12.6.3 PRODUCT PORTFOLIO 438
12.6.4 KEY DEVELOPMENTS 439
12.6.5 BUSINESS STRATEGY 440
12.6.6 SWOT ANALYSIS 441
12.7 GUERBET 442
12.7.1 OVERVIEW 442
12.7.2 FINANCIALS 443
12.7.3 PRODUCT PORTFOLIO 445
12.7.4 KEY DEVELOPMENTS 446
12.7.5 BUSINESS STRATEGY 448
12.7.6 SWOT ANALYSIS 449
12.8 LANTHEUS MEDICAL IMAGING INC. 450
12.8.1 OVERVIEW 450
12.8.2 FINANCIALS 450
12.8.3 PRODUCT PORTFOLIO 452
12.8.4 KEY DEVELOPMENTS 452
12.8.5 BUSINESS STRATEGY 453
12.8.6 SWOT ANALYSIS 454
12.9 SANOCHEMIA PHARMACEUTICAL AG 455
12.9.1 OVERVIEW 455
12.9.2 FINANCIALS 455
12.9.3 PRODUCT PORTFOLIO 455
12.9.4 KEY DEVELOPMENTS 455
12.9.5 BUSINESS STRATEGY 456
12.9.6 SWOT ANALYSIS 456
12.10 TAEJOON PHARM CO., LTD 457
12.10.1 OVERVIEW 457
12.10.2 FINANCIALS 457
12.10.3 PRODUCT PORTFOLIO 457
12.10.4 KEY DEVELOPMENTS 458
12.10.5 BUSINESS STRATEGY 458
12.10.6 SWOT ANALYSIS 459

LIST OF FIGURES

FIGURE 1 CONTRAST AGENTS GLOBAL MARKET SHARE AND REVENUE, BY REGION, (2019-2027) ($MN), 2020 (%) 33
FIGURE 2 RESEARCH METHODOLOGY: CONTRAST AGENTS GLOBAL MARKET 43
FIGURE 3 CONTRAST AGENTS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH 44
FIGURE 4 CONTRAST AGENTS GLOBAL MARKET: FORECASTING MODEL 45
FIGURE 5 CONTRAST AGENTS GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION 46
FIGURE 6 CONTRAST AGENTS GLOBAL MARKET: MARKET SEGMENTATION 54
FIGURE 7 MARKET DYNAMICS 55
FIGURE 8 CLINICAL TRIALS BY MODALITY 95
FIGURE 9 CLINICAL TRIALS BY APPLICATION AND PHASE 95
FIGURE 10 CONTRAST AGENTS GLOBAL MARKET: SUPPLY CHAIN ANALYSIS 96
FIGURE 11 CONTRAST AGENT MARKET: PORTER’S ANALYSIS 100
FIGURE 12 GLOBAL CONTRAST AGENTS GLOBAL MARKET SHARE ANALYSIS,
BY KEY PLAYERS, 2020 (%) 105
FIGURE 13 GLOBAL X-RAY/CT CONTRAST AGENTS MARKET: MAJOR PLAYER ANALYSIS (2020) (%) 109
FIGURE 14 GLOBAL MRI CONTRAST AGENTS MARKET: MAJOR PLAYER ANALYSIS
(2020) (%) 112
FIGURE 15 GLOBAL ULTRASOUND BASED CONTRAST AGENTS: MAJOR PLAYER ANALYSIS (2020) (%) 115
FIGURE 16 REGIONAL AND COUNTRYWISE CONTRAST AGENTS MEDIATED X-RAY/CT PROCEDURE VOLUME : (2020) (NO’S) 118
FIGURE 17 GLOBAL CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE (2020) ($MN) 120
FIGURE 18 NORTH AMERICA CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE, (2020) ($MN) 121
FIGURE 19 EUROPE CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE, (2020) ($MN) 122
FIGURE 20 ASIA – PACIFIC CT/X-RAY NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2020) ($MN) 124
FIGURE 21 ROW CT/ X-RAY PENETRATION, NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2020) ($MN) 125
FIGURE 22 REGIONAL AND COUNTRYWISE CONTRAST AGENTS MEDIATED MRI PROCEDURE VOLUME : (2020) (NO’S) 128
FIGURE 23 GLOBAL MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED, AND MARKET SIZE, (2020) ($MN) 130
FIGURE 24 NORTH AMERICA MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2020) ($MN) 131
FIGURE 25 EUROPE MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED MARKET SIZE, (2020) ($MN) 133
FIGURE 26 ASIA – PACIFIC MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2020) ($MN) 134
FIGURE 27 ROW MRI NUMBER OF SCANS, VOLUME OF CONTRAST AGENT CONSUMED AND MARKET SIZE, (2020) ($MN) 136
FIGURE 28 REGIONAL AND COUNTRYWISE CONTRAST AGENTS MEDIATED ULTRASOUND IMAGING PROCEDURE VOLUME: (2020) (NO’S) 138
FIGURE 29 CONTRAST AGENTS GLOBAL MARKET SHARE, BY MOLECULE
(2020 V/S 2027) (%) 143
FIGURE 30 GLOBAL IODINE BASED CONTRAST AGENTS MARKET REVENUE BY IONICITY AND NON-IONIC CONTRAST AGENTS BY CHEMICAL STRUCTURE (2020) ($MN) 147
FIGURE 31 IODINE BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2020 VS 2027) (%) 149
FIGURE 32 IODINE BASED IONIC CONTRAST AGENTS GLOBAL MARKET SHARE,
BY REGION (2020 VS 2027) (%) 151
FIGURE 33 IODINE BASED NON-IONIC CONTRAST AGENTS GLOBAL MARKET SHARE,
BY REGION (2020 V/S 2027) (%) 154
FIGURE 34 IODINE BASED NON-IONIC MONOMER CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%) 156
FIGURE 35 MACROCYCLIC GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BY IONICITY (2020 V/S 2027) (%) 163
FIGURE 36 MACROCYCLIC IONIC GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%) 166
FIGURE 37 OTHER CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION
(2020 V/S 2027) (%) 177
FIGURE 38 CONTRAST AGENTS GLOBAL MARKET SHARE, BY MODALITY
(2020 VS 2027) (%) 180
FIGURE 39 X-RAY/CT GLOBAL MARKET REVENUE, BY REGION (2020 VS 2027) (%) 183
FIGURE 40 CONTRAST AGENTS GLOBAL MARKET SHARE, BY APPLICATION (2020) (%) 191
FIGURE 41 CARDIOVASCULAR GLOBAL MARKET SHARE, BY REGION
(2020 V/S 2027) (%) 194
FIGURE 42 CANCER GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%) 198
FIGURE 43 GASTROINTESTINAL GLOBAL MARKET SHARE, BY REGION
(2020 V/S 2027) (%) 202
FIGURE 44 MUSCULOSKELETAL GLOBAL MARKET SHARE, BY REGION
(2020 V/S 2027) (%) 205
FIGURE 45 NEPHROLOGY GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%) 210
FIGURE 46 OBSTETRICS AND GYNECOLOGY GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%) 213
FIGURE 47 UROLOGY GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%) 215
FIGURE 48 OTHER APPLICATIONS GLOBAL MARKET SHARE, BY REGION
(2020 V/S 2027) (%) 217
FIGURE 49 CONTRAST AGENTS GLOBAL MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2020) ($MN) 220
FIGURE 50 INTRAVASCULAR GLOBAL MARKET SHARE, BY REGION
(2020 V/S 2027) (%) 223
FIGURE 51 ORAL GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%) 226
FIGURE 52 RECTAL GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%) 228
FIGURE 53 OTHER GLOBAL MARKET SHARE, BY REGION (2020 V/S 2027) (%) 230
FIGURE 54 CONTRAST AGENTS GLOBAL MARKET SHARE, BY IMAGING
(2020 V/S 2027) (%) 233
FIGURE 55 DIAGNOSTIC IMAGING GLOBAL MARKET SHARE, BY REGION
(2020 V/S 2027) (%) 236
FIGURE 56 CONTRAST AGENTS GLOBAL MARKET SHARE, BY END-USERS,
(2020 V/S 2027) (%) 241
FIGURE 57 HOSPITAL GLOBAL MARKET SHARE, BY END-USERS, (2020 V/S 2027) (%) 244
FIGURE 58 OTHER END-USER GLOBAL MARKET SHARE, BY REGION,
(2020 V/S 2027) (%) 248
FIGURE 59 CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%) 251
FIGURE 60 CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION AND COUNTRY (2020) ($MN) 252
FIGURE 61 NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY MOLECULE
(2020 V/S 2027) (%) 264
FIGURE 62 NORTH AMERICA IODINE BASED CONTRAST AGENTS MARKET REVENUE,
BY IONICITY AND CHEMICAL STRUCTURE, (2020) ($MN) 265
FIGURE 63 NORTH AMERICA GADOLINIUM-BASED CONTRAST AGENTS MARKET SHARE, BY CHEMICAL STRUCTURE, (2020 V/S 2027) (%) 266
FIGURE 64 NORTH AMERICA GADOLINIUM-BASED CONTRAST AGENTS MARKET SHARE, BY IONOCITY, (2020 V/S 2027) (%) 267
FIGURE 65 NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY MODALITY, (2020 VS 2027) (%) 268
FIGURE 66 NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY APPLICATION, (2020) (%) 269
FIGURE 67 NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY ROUTE OF ADMINISTRATION, (2020 VS 2027) (%) 270
FIGURE 68 NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY IMAGING,
(2020 VS 2027) (%) 271
FIGURE 69 NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY END-USER, (2020 VS 2027) (%) 272
FIGURE 70 NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY COUNTRY,
(2020 V/S 2027) (%) 274
FIGURE 71 U.S. CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN) 279
FIGURE 72 U.S. CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN) 280
FIGURE 73 U.S. CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND
BY END-USER, (2020 V/S 2027) ($MN) 281
FIGURE 74 REST OF NORTH AMERICAN COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN) 285
FIGURE 75 REST OF NORTH AMERICAN COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND ROUTE OF ADMINISTRATION,
(2020 VS 2027) ($MN) 286
FIGURE 76 REST NORTH AMERICAN COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND BY END-USER, (2020 V/S 2027) ($MN) 287
FIGURE 77 EUROPE CONTRAST AGENTS MARKET SHARE, BY MOLECULE
(2020 V/S 2027) (%) 297
FIGURE 78 EUROPE IODINE BASED CONTRAST AGENTS REVENUE, BY IONICITY AND BY CHEMICAL STRUCTURE, (2020) ($MN) 298
FIGURE 79 EUROPE GADOLINIUM BASED CONTRAST AGENTS MARKET SHARE,
BY CHEMICAL STRUCTURE, (2020 VS 2027) (%) 299
FIGURE 80 EUROPE GADOLINIUM MACROCYCLIC BASED CONTRAST AGENTS MARKET SHARE, BY IONICITY, (2020 VS 2027) (%) 300
FIGURE 81 EUROPE CONTRAST AGENTS MARKET SHARE, BY MODALITY,
(2020 V/S 2027) (%) 301
FIGURE 82 EUROPE CONTRAST AGENTS MARKET SHARE, BY APPLICATION, (2020) (%) 302
FIGURE 83 EUROPE CONTRAST AGENTS MARKET SHARE, BY ROUTE OF ADMINISTRATION (2020 V/S 2027) (%) 303
FIGURE 84 EUROPE CONTRAST AGENTS MARKET SHARE, BY IMAGING
(2020 V/S 2027) (%) 304
FIGURE 85 EUROPE CONTRAST AGENTS MARKET SHARE, BY END-USER
(2020 V/S 2027) (%) 305
FIGURE 86 EUROPE CONTRAST AGENTS MARKET SHARE, BY COUNTRY,
(2020 V/S 2027) (%) 307
FIGURE 87 GERMANY CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND
BY MODALITY, (2020 V/S 2027) ($MN) 310
FIGURE 88 GERMANY CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND
BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN) 311
FIGURE 89 GERMANY CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND
BY END-USER, (2020 V/S 2027) ($MN) 312
FIGURE 90 FRANCE CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND
BY MODALITY, (2020 V/S 2027) ($MN) 316
FIGURE 91 FRANCE CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND
BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN) 317
FIGURE 92 FRANCE CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND
BY END-USER, (2020 V/S 2027) ($MN) 318
FIGURE 93 U.K. CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND
BY MODALITY, (2020 V/S 2027) ($MN) 321
FIGURE 94 U.K. CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND
BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN) 322
FIGURE 95 U.K. CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND BY
END-USER, (2020 V/S 2027) ($MN) 323
FIGURE 96 REST OF EUROPE CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN) 326
FIGURE 97 REST OF EUROPE CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN) 327
FIGURE 98 REST OF EUROPE CONTRAST AGENTS MARKET REVENUE, BY IMAGING, AND BY END –USER (2020 V/S 2027) ($MN) 328
FIGURE 99 ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY MOLECULE
(2020 V/S 2027) (%) 338
FIGURE 100 ASIA-PACIFIC IODINE BASED CONTRAST AGENTS MARKET SHARE BY IONICITY AND CHEMICAL STRUCTURE, (2020) ($MN) 339
FIGURE 101 ASIA-PACIFIC GADOLINIUM-BASED CONTRAST AGENTS MARKET SHARE,
BY CHEMICAL STRUCTURE, (2020 V/S 2027) (%) 340
FIGURE 102 ASIA-PACIFIC MACROCYCLIC - BASED CONTRAST AGENTS MARKET SHARE, BY IONOCITY, (2020 V/S 2027) (%) 341
FIGURE 103 ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY MODALITY,
(2020 V/S 2027) (%) 342
FIGURE 104 ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY APPLICATION, (2020) ($MN) 343
FIGURE 105 ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY ROUTE OF ADMINISTRATION (2020 V/S 2027) (%) 344
FIGURE 106 ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY IMAGING
(2020 V/S 2027) (%) 345
FIGURE 107 ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY END-USER
(2020 V/S 2027) (%) 346
FIGURE 108 ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY COUNTRY,
(2020 V/S 2027) (%) 348
FIGURE 109 JAPANCONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND
BY MODALITY, (2020 V/S 2027) ($MN) 351
FIGURE 110 JAPAN CONTRAST AGENTS MARKET REVENUE,BY APPLICATION AND
BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN) 352
FIGURE 111 JAPAN CONTRAST AGENTS MARKET REVENUE BY IMAGING AND BY
END-USER, (2020 V/S 2027) ($MN) 353
FIGURE 112 CHINACONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND
BY MODALITY, (2020 V/S 2027) ($MN) 357
FIGURE 113 CHINA CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND
BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN) 358
FIGURE 114 CHINA CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND BY
END-USER, (2020 V/S 2027) ($MN) 359
FIGURE 115 SOUTH KOREACONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN) 362
FIGURE 116 SOUTH KOREA CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN) 363
FIGURE 117 SOUTH KOREA CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND BY END-USER, (2020 V/S 2027) ($MN) 364
FIGURE 118 REST OF APAC CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN) 368
FIGURE 119 REST OF APAC CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN) 369
FIGURE 120 REST OF APAC CONTRAST AGENTS MARKET REVENUE CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND BY END-USER (2020 V/S 2027) ($MN) 370
FIGURE 121 REST OF THE WORLD CONTRAST AGENTS MARKET SHARE, BY MOLECULE (2020 V/S 2027) (%) 380
FIGURE 122 REST OF THE WORLD IODINE BASED CONTRAST AGENT MARKET REVENUE BY IONICITY AND BY CHEMICAL STRUCTURE, (2020) ($MN) 381
FIGURE 123 REST OF THE WORLD GADOLINIUM-BASED CONTRAST AGENTS MARKET SHARE, BY CHEMICAL STRUCTURE, (2020 V/S 2027) (%) 382
FIGURE 124 REST OF THE WORLD MACROCYCLIC BASED CONTRAST AGENTS MARKET SHARE, BY CHEMICAL STRUCTURE (2020 V/S 2027) (%) 383
FIGURE 125 REST OF THE WORLD CONTRAST AGENTS MARKET SHARE, BY MODALITY, (2020 VS 2027) (%) 384
FIGURE 126 REST OF THE WORLD CONTRAST AGENTS MARKET REVENUE,
BY APPLICATION, (2020) ($MN) 385
FIGURE 127 REST OF THE WORLD CONTRAST AGENTS MARKET SHARE, BY ROUTE OF ADMINISTRATION, (2020 VS 2027) (%) 386
FIGURE 128 REST OF THE WORLD CONTRAST AGENTS MARKET SHARE, BY IMAGING, (2020 VS 2027) (%) 387
FIGURE 129 REST OF THE WORLD CONTRAST AGENTS MARKET SHARE, BY END-USER, (2020 VS 2027) (%) 388
FIGURE 130 REST OF THE WORLD CONTRAST AGENTS MARKET SHARE, BY COUNTRY, (2020 V/S 2027) (%) 389
FIGURE 131 TURKEY CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN) 392
FIGURE 132 TURKEY CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN) 393
FIGURE 133 TURKEY CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND
BY END-USER, (2020 V/S 2027) ($MN) 394
FIGURE 134 BRAZIL CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN) 397
FIGURE 135 BRAZIL CONTRAST AGENTS MARKET REVENUE, BY APPLICATION AND BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN) 398
FIGURE 136 BRAZIL CONTRAST AGENTS MARKET REVENUE, BY IMAGING, AND BY
END-USER (2020 V/S 2027) ($MN) 399
FIGURE 137 LATAM AND MIDDLE EAST & AFRICA CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2020 V/S 2027) ($MN) 402
FIGURE 138 LATAM AND MIDDLE EAST & AFRICA CONTRAST AGENT MARKET REVENUE, BY APPLICATION AND BY ROUTE OF ADMINISTRATION, (2020 VS 2027) ($MN) 403
FIGURE 139 LATAM AND MIDDLE EAST & AFRICA CONTRAST AGENTS MARKET REVENUE, BY IMAGING AND BY END-USER, (2020 V/S 2027) ($MN) 404
FIGURE 140 KEY GROWTH STRATEGIES (2019 – 2020) 406
FIGURE 141 SWOT: BAYER GROUP 418
FIGURE 142 SWOT: BEIJING BEILU PHARMACEUTICAL CO., LTD. 421
FIGURE 143 SWOT: BRACCO GROUP 426
FIGURE 144 SWOT: DONGKOOK LIFE SCIENCE 429
FIGURE 145 SWOT: FUJIPHARMA CO LTD 434
FIGURE 146 SWOT: GE HEALTHCARE 441
FIGURE 147 SWOT: GUERBET 449
FIGURE 148 SWOT: LANTHEUS MEDICAL IMAGING INC. 454
FIGURE 149 SWOT: SANOCHEMIA PHARMACEUTICAL AG 456
FIGURE 150 SWOT: TAEJOON PHARM CO., LTD. 459

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+